{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:54:14Z","timestamp":1793534054650,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunologically mediated clearance of senescent cells has been demonstrated in several model systems. Given increasing evidence for these cells promoting tumor pathology and immune escape, we sought to examine whether a vaccine against senescent cells can lead to tumor regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A senolytic dendritic cell (DC) immunotherapy (\u201cSenoVax\u2122\u201d) was created by pulsing DCs with lysate from in vitro generated syngeneic senescent fibroblasts. Prophylactic and therapeutic activity of SenoVax on tumor growth and metastasis was assessed in the Lewis Lung Carcinoma (LLC) model. The immunogenicity of SenoVax\u2122 was measured using cytotoxicity, proliferation, and cytokine assays. Adoptive transfer of lymphocytes from vaccinated mice into na\u00efve mice was performed in a prophylactic tumor challenge model. Assessment of plasma senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 was performed by ELISA. Synergy of SenoVax\u2122 with immune checkpoint inhibitors and the universality of the vaccine\u2019s effects against other tumors was assessed. Furthermore, induction of autoimmunity was assessed by complement activation and autoantibody formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SenoVax\u2122 was created by pulsing DC with cell lysate from senescent fibroblasts, producing DCs that expressed co-stimulatory molecules, stimulated T cell proliferation, and expressed the senescence antigen p16. SenoVax\u2122 induced prophylactic and therapeutic tumor regression in LLC primary and metastatic murine tumor models. T cell proliferative and cytokine recall responses towards senescent cells but not to control stromal cell pulsed DCs were detected in vaccinated mice. Additionally, reduction in senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 were observed. Adoptive transfer experiments revealed a role for CD8+ T cells in transplanting protection. When SenoVax\u2122 was administered in combination with anti-PD-L1 or anti-CTLA-4 antibodies, the data showed synergistic effects in reducing tumor growth. SenoVax\u2122 also demonstrated reduction of GL281 glioma, Pan01 pancreatic cancer, and 4T1 breast cancer cell growth. No significant activation of complement or induction of autoantibodies was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vaccination with DC pulsed senescent cells resulted in reduction of tumor growth in a CD8+ T cell and interferon gamma-associated manner in lung cancer as well as other tumor models. The data provide mechanistic support for advancement of senolytic immunotherapy as a novel form of cancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07393-3","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:40:36Z","timestamp":1764330036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reduction of solid tumors by senescent cell immunization"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-374X","authenticated-orcid":false,"given":"Thomas E.","family":"Ichim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladyslav","family":"Bykoriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Fortunati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karenjan A.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Minev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bajnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris N.","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"3","key":"7393_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7393_CR2","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7393_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"7393_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/0284186X.2021.2013529","volume":"61","author":"L Lofling","year":"2022","unstructured":"Lofling L, et al. Temporal trends in lung cancer survival: a population-based study. Acta Oncol. 2022;61(5):625\u201331.","journal-title":"Acta Oncol"},{"issue":"11","key":"7393_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nrc2947","volume":"10","author":"W Pao","year":"2010","unstructured":"Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11):760\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"7393_CR6","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1097\/MS9.0000000000002717","volume":"86","author":"T Rais","year":"2024","unstructured":"Rais T, et al. Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer. Ann Med Surg (Lond). 2024;86(12):7265\u201369.","journal-title":"Ann Med Surg (Lond)"},{"key":"7393_CR7","doi-asserted-by":"publisher","first-page":"964743","DOI":"10.1155\/2013\/964743","volume":"2013","author":"M Roy","year":"2013","unstructured":"Roy M, et al. Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int. 2013;2013:964743.","journal-title":"Biomed Res Int"},{"key":"7393_CR8","doi-asserted-by":"publisher","first-page":"1451230","DOI":"10.3389\/fonc.2024.1451230","volume":"14","author":"L Yu","year":"2024","unstructured":"Yu L, et al. Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials. Front Oncol. 2024;14:1451230.","journal-title":"Front Oncol"},{"key":"7393_CR9","doi-asserted-by":"publisher","first-page":"918709","DOI":"10.3389\/fphar.2022.918709","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, et al. Programmed cell death protein 1\/Programmed cell death protein ligand 1 immunosuppressants in advanced non-small cell lung cancer research progress in treatment. Front Pharmacol. 2022;13:918709.","journal-title":"Front Pharmacol"},{"issue":"8","key":"7393_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856\u201364.","journal-title":"Clin Cancer Res"},{"key":"7393_CR11","doi-asserted-by":"publisher","first-page":"251513552090423","DOI":"10.1177\/2515135520904238","volume":"8","author":"J Belizario","year":"2020","unstructured":"Belizario J, Destro Rodrigues MF. Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8(+) T-cell activation and exhaustion. Ther Adv Vaccines Immunother. 2020;8:2515135520904238.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"7393_CR12","doi-asserted-by":"crossref","unstructured":"Balanca CC, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight. 2021;6(2).","DOI":"10.1172\/jci.insight.142513"},{"issue":"1","key":"7393_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195\u2013211 e10.","journal-title":"Immunity"},{"issue":"1","key":"7393_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete AR, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016;6(1):71\u201379.","journal-title":"Cancer Discov"},{"key":"7393_CR15","doi-asserted-by":"publisher","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou S, Yang H. Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies. Front Immunol. 2023;14:1129465.","journal-title":"Front Immunol"},{"key":"7393_CR16","doi-asserted-by":"publisher","first-page":"1457189","DOI":"10.3389\/fimmu.2024.1457189","volume":"15","author":"J Ge","year":"2024","unstructured":"Ge J, Yin X, Chen L. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. Front Immunol. 2024;15:1457189.","journal-title":"Front Immunol"},{"key":"7393_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molimm.2024.08.004","volume":"174","author":"NL Mani","year":"2024","unstructured":"Mani NL, et al. Acidity induces durable enhancement of T(reg) cell suppressive functions for tumor immune evasion. Mol Immunol. 2024;174:57\u201368.","journal-title":"Mol Immunol"},{"issue":"1","key":"7393_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12672-023-00787-z","volume":"14","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, et al. Breast cancer stem cells generate immune-suppressive T regulatory cells by secreting TGFbeta to evade immune-elimination. Discov Oncol. 2023;14(1):220.","journal-title":"Discov Oncol"},{"key":"7393_CR19","unstructured":"Li MY, Ye W, Luo KW. Immunotherapies targeting tumor-associated Macrophages (TAMs) in cancer. Pharmaceutics. 2024;16(7)."},{"issue":"19","key":"7393_CR20","doi-asserted-by":"publisher","first-page":"e2310318","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. Engineering and targeting neutrophils for cancer therapy. Adv Mater. 2024;36(19):e2310318.","journal-title":"Adv Mater"},{"key":"7393_CR21","doi-asserted-by":"crossref","unstructured":"Rajkumari S, et al. Myeloid-derived suppressor cells in cancer: current knowledge and future perspectives. Int Immunopharmacol. 2024;142(Pt A):112949.","DOI":"10.1016\/j.intimp.2024.112949"},{"issue":"1","key":"7393_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s43556-024-00233-8","volume":"5","author":"K Lv","year":"2024","unstructured":"Lv K, He T. Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets. Mol Biomed. 2024;5(1):70.","journal-title":"Mol Biomed"},{"issue":"5","key":"7393_CR23","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.4049\/jimmunol.177.5.3448","volume":"177","author":"G Bellone","year":"2006","unstructured":"Bellone G, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. The J Immunol. 2006;177(5):3448\u201360.","journal-title":"The J Immunol"},{"issue":"1","key":"7393_CR24","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1038\/s41467-024-50441-7","volume":"15","author":"B Assouline","year":"2024","unstructured":"Assouline B, et al. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8(+) T cell activation and limit responsiveness to immunotherapy in mice. Nat Commun. 2024;15(1):6162.","journal-title":"Nat Commun"},{"issue":"23","key":"7393_CR25","doi-asserted-by":"publisher","first-page":"e2400945","DOI":"10.1002\/adhm.202400945","volume":"13","author":"P Ji","year":"2024","unstructured":"Ji P, et al. Targeted clearance of senescent cells via engineered extracellular vesicles reprograms tumor immunosuppressive microenvironment. Adv Healthc Mater. 2024;13(23):e2400945.","journal-title":"Adv Healthc Mater"},{"issue":"12","key":"7393_CR26","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.18632\/aging.205975","volume":"16","author":"J Pessoa","year":"2024","unstructured":"Pessoa J, Nobrega-Pereira S, de Jesus BB. Senescent cell-derived vaccines: a new concept towards an immune response against cancer and aging? Aging (albany NY). 2024;16(12):10657\u201365.","journal-title":"Aging (albany NY)"},{"issue":"22","key":"7393_CR27","doi-asserted-by":"publisher","first-page":"e2300121","DOI":"10.1002\/advs.202300121","volume":"10","author":"L Diao","year":"2023","unstructured":"Diao L, Liu M. Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell. Adv Sci (Weinh). 2023;10(22):e2300121.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"7393_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328\u201332.","journal-title":"Nat Med"},{"issue":"3","key":"7393_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0022-5347(01)61767-1","volume":"161","author":"L Holtl","year":"1999","unstructured":"Holtl L, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161(3):777\u201382.","journal-title":"J Urol"},{"key":"7393_CR30","doi-asserted-by":"crossref","unstructured":"Inoue C, et al. Cancer-associated fibroblast marker signatures and stromal composition in usual interstitial pneumonia-associated lung adenocarcinoma: an analysis using a proteomic-immunohistochemical approach. Virchows Arch. 2025.","DOI":"10.1007\/s00428-025-04254-8"},{"issue":"1","key":"7393_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12964-025-02369-8","volume":"23","author":"H Huang","year":"2025","unstructured":"Huang H, et al. Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma. Cell Commun Signal. 2025;23(1):379.","journal-title":"Cell Commun Signal"},{"key":"7393_CR32","doi-asserted-by":"crossref","unstructured":"O\u2019Fee K, et al. Targeting Cancer-associated Fibroblasts (CAFs) to optimize radiation responses. Cancer J. 2025;31(4).","DOI":"10.1097\/PPO.0000000000000776"},{"key":"7393_CR33","doi-asserted-by":"publisher","first-page":"1635771","DOI":"10.3389\/fimmu.2025.1635771","volume":"16","author":"G Ruan","year":"2025","unstructured":"Ruan G, et al. Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy. Front Immunol. 2025;16:1635771.","journal-title":"Front Immunol"},{"key":"7393_CR34","doi-asserted-by":"publisher","first-page":"101273","DOI":"10.1016\/j.drup.2025.101273","volume":"82","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors. Drug Resist Updat. 2025;82:101273.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"7393_CR35","doi-asserted-by":"publisher","first-page":"111612","DOI":"10.1016\/j.isci.2024.111612","volume":"28","author":"L Liu","year":"2025","unstructured":"Liu L, et al. Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer. iScience. 2025;28(1):111612.","journal-title":"iScience"},{"issue":"6","key":"7393_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/0008-5472.CAN-24-1185","volume":"85","author":"Z Ou","year":"2025","unstructured":"Ou Z, et al. Hypoxia-induced senescent fibroblasts secrete IGF1 to promote cancer stemness in esophageal squamous cell carcinoma. Cancer Res. 2025;85(6):1064\u201381.","journal-title":"Cancer Res"},{"issue":"12","key":"7393_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/gtc.13177","volume":"29","author":"T Yamashita","year":"2024","unstructured":"Yamashita T, et al. Immunotherapy-induced reprogramming of cancer-associated fibroblasts can promote tumor progression. Genes Cells. 2024;29(12):1275\u201383.","journal-title":"Genes Cells"},{"issue":"9","key":"7393_CR38","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.4251\/wjgo.v16.i9.3980","volume":"16","author":"H Jiang","year":"2024","unstructured":"Jiang H, et al. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. World J Gastrointest Oncol. 2024;16(9):3980\u201393.","journal-title":"World J Gastrointest Oncol"},{"key":"7393_CR39","doi-asserted-by":"publisher","first-page":"155418","DOI":"10.1016\/j.prp.2024.155418","volume":"260","author":"C Inoue","year":"2024","unstructured":"Inoue C, et al. Dipeptidyl peptidase 4-positive cancer-associated fibroblasts enhance lung adenocarcinoma growth. Pathol Res Pract. 2024;260:155418.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"7393_CR40","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/2159-8290.CD-23-0426","volume":"14","author":"J Ye","year":"2024","unstructured":"Ye J, et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discov. 2024;14(7):1302\u201323.","journal-title":"Cancer Discov"},{"issue":"7","key":"7393_CR41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/2159-8290.CD-23-0428","volume":"14","author":"JI Belle","year":"2024","unstructured":"Belle JI, et al. Senescence defines a distinct subset of myofibroblasts that orchestrates immunosuppression in pancreatic cancer. Cancer Discov. 2024;14(7):1324\u201355.","journal-title":"Cancer Discov"},{"key":"7393_CR42","doi-asserted-by":"publisher","first-page":"11762","DOI":"10.1038\/ncomms11762","volume":"7","author":"MK Ruhland","year":"2016","unstructured":"Ruhland MK, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016;7:11762.","journal-title":"Nat Commun"},{"issue":"3\u20134","key":"7393_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0966-3274(03)00048-0","volume":"11","author":"TE Ichim","year":"2003","unstructured":"Ichim TE, Zhong R, Min WP. Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol. 2003;11(3\u20134):295\u2013306.","journal-title":"Transpl Immunol"},{"key":"7393_CR44","doi-asserted-by":"publisher","first-page":"621324","DOI":"10.1155\/2015\/621324","volume":"2015","author":"A Kellar","year":"2015","unstructured":"Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: clinical trial applications. Biomed Res Int. 2015;2015:621324.","journal-title":"Biomed Res Int"},{"issue":"6","key":"7393_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s002800050773","volume":"41","author":"RS Herbst","year":"1998","unstructured":"Herbst RS, Takeuchi H, Teicher BA. Paclitaxel\/Carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol. 1998;41(6):497\u2013504.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"7393_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000007277","volume":"46","author":"A Papageorgiou","year":"2000","unstructured":"Papageorgiou A, et al. Effect of navelbine on inhibition of tumor growth, cellular differentiation and estrogen receptor status on Lewis lung carcinoma. Chemotherapy. 2000;46(3):188\u201394.","journal-title":"Chemotherapy"},{"issue":"1","key":"7393_CR47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12885-018-4738-2","volume":"18","author":"RS Qin","year":"2018","unstructured":"Qin RS, et al. Enhanced antitumor and anti-angiogenic effects of metronomic vinorelbine combined with endostar on Lewis lung carcinoma. BMC Cancer. 2018;18(1):967.","journal-title":"BMC Cancer"},{"issue":"1","key":"7393_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1269\/jrr.10013","volume":"52","author":"HP Zhang","year":"2011","unstructured":"Zhang HP, et al. Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res. 2011;52(1):1\u20138.","journal-title":"J Radiat Res"},{"issue":"7","key":"7393_CR49","doi-asserted-by":"publisher","first-page":"e101720","DOI":"10.1371\/journal.pone.0101720","volume":"9","author":"P Wang","year":"2014","unstructured":"Wang P, et al. Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice. PLoS One. 2014;9(7):e101720.","journal-title":"PLoS One"},{"issue":"29","key":"7393_CR50","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","volume":"24","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721\u201330.","journal-title":"J Clin Oncol"},{"key":"7393_CR51","unstructured":"https:\/\/www.cancernetwork.com\/view\/ecc-lung-cancer-vaccine-trial-fails-meet-endpoint-shows-benefit-some-patients#"},{"issue":"13","key":"7393_CR52","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","volume":"24","author":"MB Faries","year":"2017","unstructured":"Faries MB, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991\u20134000.","journal-title":"Ann Surg Oncol"},{"key":"7393_CR53","unstructured":"Slingluff CL, et al. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer. 2021;9(10)."},{"issue":"2","key":"7393_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.biologicals.2015.12.005","volume":"44","author":"J Petricciani","year":"2016","unstructured":"Petricciani J, Koren E, Morton D. Analysis of the in vivo proliferative capacity of a whole cell cancer vaccine. Biologicals. 2016;44(2):60\u201363.","journal-title":"Biologicals"},{"key":"7393_CR55","doi-asserted-by":"publisher","first-page":"203636132311795","DOI":"10.1177\/20363613231179541","volume":"15","author":"A Fareed","year":"2023","unstructured":"Fareed A, et al. Dcvax: a promising advancement in oncology for the treatment of glioblastoma. Rare Tumors. 2023;15:20363613231179541.","journal-title":"Rare Tumors"},{"issue":"4","key":"7393_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1517\/13543780902841951","volume":"18","author":"CJ Wheeler","year":"2009","unstructured":"Wheeler CJ, Black KL. Dcvax-brain and dc vaccines in the treatment of GBM. Expert Opin Investig Drugs. 2009;18(4):509\u201319.","journal-title":"Expert Opin Investig Drugs"},{"key":"7393_CR57","doi-asserted-by":"publisher","first-page":"1404861","DOI":"10.3389\/fimmu.2024.1404861","volume":"15","author":"L Ridolfi","year":"2024","unstructured":"Ridolfi L, et al. First step results from a phase ii study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax). Front Immunol. 2024;15:1404861.","journal-title":"Front Immunol"},{"key":"7393_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12967-016-0842-8","volume":"14","author":"SC Wagner","year":"2016","unstructured":"Wagner SC, et al. Safety of targeting tumor endothelial cell antigens. J Transl Med. 2016;14:90.","journal-title":"J Transl Med"},{"issue":"17","key":"7393_CR59","doi-asserted-by":"publisher","first-page":"28595","DOI":"10.18632\/oncotarget.15563","volume":"8","author":"SC Wagner","year":"2017","unstructured":"Wagner SC, et al. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget. 2017;8(17):28595\u2013613.","journal-title":"Oncotarget"},{"issue":"13","key":"7393_CR60","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","volume":"17","author":"J Lohr","year":"2011","unstructured":"Lohr J, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res. 2011;17(13):4296\u2013308.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7393_CR61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2176\/nmc.41.253","volume":"41","author":"A Sasaki","year":"2001","unstructured":"Sasaki A, et al. Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells. Neurol Med Chir (tokyo). 2001;41(5):253\u201358; discussion 258-9.","journal-title":"Neurol Med Chir (tokyo)"},{"issue":"9","key":"7393_CR62","first-page":"60","volume":"122","author":"K Kluckova","year":"2021","unstructured":"Kluckova K, Durmanova V, Bucova M. Soluble HLA-G, its diagnostic and prognostic value and potential target molecule for future therapy in cancer. Bratisl Lek Listy. 2021;122(9):60\u2013617.","journal-title":"Bratisl Lek Listy"},{"key":"7393_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","volume":"34","author":"SK Mittal","year":"2015","unstructured":"Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22\u201327.","journal-title":"Curr Opin Immunol"},{"key":"7393_CR64","doi-asserted-by":"publisher","first-page":"1637191","DOI":"10.3389\/fimmu.2025.1637191","volume":"16","author":"P Upadhyay","year":"2025","unstructured":"Upadhyay P, et al. Mechanistic insights and biomarker discovery in immune cell aging and age-associated diseases. Front Immunol. 2025;16:1637191.","journal-title":"Front Immunol"},{"issue":"3","key":"7393_CR65","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","volume":"5","author":"S Chaib","year":"2024","unstructured":"Chaib S, et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat Cancer. 2024;5(3):448\u201362.","journal-title":"Nat Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07393-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:06:15Z","timestamp":1781618775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07393-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7393"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07393-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7837498\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have reviewed and approved the submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work was supported by Immorta Bio Inc, a scientific longevity company focused on treating disease of aging and aging as disease with over 25 patents pending. TEI, VB, AR are management and shareholders of Immorta Bio Inc. GL is a member of the Scientific Advisory Board of Immorta Bio Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1365"}}